Company Overview

Viatris Inc., together with its subsidiaries, operates as a global healthcare company focused on providing a wide range of pharmaceutical products. The company was formed in November 2020 through the combination of Upjohn, a subsidiary of Pfizer specializing in off-patent drugs, and Mylan, a global pharmaceutical manufacturer focused on generic and specialty drugs. This merger created one of the largest generic drug manufacturers globally, serving over 165 countries.

Viatris operates in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, the rest of Asia, Africa, Latin America, and the Middle East. Its business is structured across four key segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets.

Business Segments and Products

Viatris employs a diversified business model across multiple geographic regions, offering a broad portfolio of pharmaceutical products.

Product Portfolio

The company offers a comprehensive range of products including prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. Generics (both commoditized and complex) and biosimilars account for approximately 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes well-known brands like Lipitor, Norvasc, Lyrica, and Viagra.

Therapeutic Areas

Viatris provides drugs across various therapeutic areas, addressing both noncommunicable and infectious diseases. These include:

- Cardiovascular

- CNS and Anesthesia

- Dermatology

- Diabetes and Metabolism

- Eye Care

- Gastroenterology

- Immunology

- Oncology

- Respiratory and Allergy

In addition to medicines, the company offers support services such as diagnostic clinics, educational seminars, and digital tools to assist patients in managing their health more effectively.

Brand Portfolio

Key brands in Viatris' portfolio include Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna.

Financial Performance

Market Capitalization and Trading Information

- Market Cap (intraday): $11.192 Billion (as of September 23, 2025)

Revenue Performance

- Revenue (TTM): $14.11 Billion USD

- Revenue (2024): $14.73 Billion USD

- Revenue (2023): $15.42 Billion USD (decrease from 2023)

Key Financial Results

- First Quarter 2025:

- Total revenue was $3.3 billion, down 11% on a reported basis and down 2% on a divestiture-adjusted operational basis compared to Q1 2024. This was primarily driven by the negative Indore Impact.

- Excluding the Indore Impact, total revenues would have increased by 2% on a divestiture-adjusted operational basis compared to Q1 2024.

- Second Quarter 2025:

- Viatris Inc. reported strong second quarter 2025 financial results and reiterated its 2025 financial guidance ranges across all metrics.

New Product Performance

- New Product Revenues (Current Quarter): Approximately $85 million

- New Product Revenues (Year-to-Date): Approximately $582 million

- Projected New Product Revenues (2025): $450 million to $550 million

Key Strategic Initiatives

Pipeline Development

Viatris focuses on innovation across more than 10 major therapeutic areas, with specific strategic emphasis on dermatology, ophthalmology, and gastroenterology for future development.

The company is advancing its pipeline, with several important late-stage development milestones including:

- Selatogrel

- Cenerimod

- Sotagliflozin

- Six Phase 3 readouts

Capital Allocation and Shareholder Returns

- 2025 Capital Returns:

- The company has returned over $630 million to shareholders, including $350 million in share buybacks, as of May 8, 2025.

- Viatris reaffirms its 2025 capital allocation priorities, focusing on share repurchases.

- Debt Reduction:

- The company paid down approximately $1.4 billion in debt in Q4 (and approximately $3.7 billion for the full year).

- Viatris achieved its long-term gross leverage target, ending the year at 2.9x.

Regulatory Challenges

Indore Facility Impact

The "Indore Impact" refers to the estimated negative financial impact on 2025 total revenues and earnings from operations versus comparable 2024 periods. This is due to the FDA issuing a warning letter and import alert related to the company's oral finished dose manufacturing facility in Indore, India.

- Estimated Negative Impact on Q1 2025 Total Revenues: Approximately $140 million.

- Estimated Negative Impact on Full Year 2025 Total Revenues: Approximately $500 million.

- Estimated Negative Impact on Full Year 2025 Adjusted EBITDA: Approximately $385 million.

Distribution and Market Reach

Viatris offers its medicines in various forms, including oral solid doses, injectables, and complex dosage forms. Its customers include retail and pharmacy establishments, wholesalers and distributors, payers, insurers, governments, and institutions.

The company distributes its products through multiple channels:

- Pharmaceutical wholesalers/distributors

- Pharmaceutical retailers

- Institutional pharmacies

- Mail-order and e-commerce pharmacies

- Specialty pharmacies

With a mission to empower people worldwide to live healthier at every stage of life, Viatris provides access to high-quality medicines at scale. It currently supplies approximately 1 billion patients around the world annually, touching all stages of life from birth to end-of-life, and addressing acute conditions to chronic diseases.

Viatris represents a significant player in the global pharmaceutical industry, combining the scale advantages of generic drug manufacturing with a robust portfolio of established brand medications. Despite facing regulatory headwinds from its Indore facility, the company continues to demonstrate resilience through its diversified global operations, commitment to returning capital to shareholders, and advancement of its pipeline of innovative products.